Navigation Links
FDA Approves Cymbalta(R) for the Management of Fibromyalgia
Date:6/16/2008

Cymbalta Reduces Pain and Improves Functioning in Fibromyalgia Patients

INDIANAPOLIS, June 16 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company (NYSE: LLY) announced today. Cymbalta is the first serotonin- norepinephrine reuptake inhibitor with proven efficacy for reducing pain in patients with fibromyalgia. The fibromyalgia indication represents the second FDA-approved use for Cymbalta for a pain disorder, demonstrating the medication's analgesic effect.

"The approval of Cymbalta is important because it provides physicians and patients with a new treatment option shown to help reduce pain and improve functioning in this difficult-to-treat disorder," said Madelaine Wohlreich, M.D., medical advisor and research physician at Lilly.

The cause of fibromyalgia remains unknown; however, scientists believe it may be related to some combination of changes in brain and spinal cord chemistry,(i) genetics(ii) and stress(iii). Some researchers believe fibromyalgia is a disorder of increased sensitivity to pain. Although the way Cymbalta works in people is not fully known, medical experts believe it increases the activity of two naturally occurring substances called serotonin and norepinephrine. These substances aid communication in many areas of the brain and spinal cord that affect emotion. Research also suggests that these substances are part of the body's natural pain-suppressing system.

"The FDA approval of Cymbalta for the management of fibromyalgia is another important step in the efforts to ensure that people with fibromyalgia will have the availability of effective
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobaccos Harm
2. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
3. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
4. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
5. FDA Approves Health Claim for Brown Rice
6. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
7. FDA approves HeartMate II mechanical heart pump for heart-failure patients
8. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
9. FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
10. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
11. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... If you think winning is one of the key ... Winning along with other mental bonuses ranked near the bottom ... one of 11 big fun factors, according to a new ... when it comes to the "fun" factor, very little research ... into this elusive conceptuntil now. , The results of this ...
(Date:7/9/2014)... Medicine at the University of Pennsylvania in collaboration with ... million grant from the National Cancer Institute (NCI) to ... patients with malignant pleural mesothelioma, a rare, aggressive and ... lining of the lungs and is caused almost exclusively ... clinical trial and additional studies looking at the effects ...
(Date:7/9/2014)... stromal support cells and immune cells and the ... the development of diseases could open new therapeutic ... the conclusion of a review article by scientists from ... Nature . , Prof. Peter Carmeliet: "Consider the review ... cancer cells has been examined in minute detail for ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... than watching World Cup highlights, Brian Williams refreshing old ... unfortunate positions on railings. A University of Colorado Cancer ... shows that YouTube also allows researchers, journals, and ... topics of skin cancer and prevention. , "No matter ... of how we communicate around the world," says Chante ...
Breaking Medicine News(10 mins):Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... dressing well given by an emergency doctor. There is no need ... cold. A brisk walk and exposure to sunlight will do you ... you want to avoid the ill-effects of cold weather. Just putting ... the answer. ,Dr Goerge Danke, professor of emergency medicine ...
... According to new study, a protein in the eye has ... researchers say this could lead to promising treatments for other// ... ,Scientists from the Schepens Eye Research Institute in Boston ... a therapeutic drug. The drug can then prevent the onset ...
... that breathing oxygen may cause some harm to cells. The ... people //with severe lung or heart disease.Oxygen supports the organs ... the blood. But oxygen is often given inappropriately. Overall the ... life'. ,A study by researchers at New York Medical ...
... at University of Illinois at Chicago could possibly help ... Dean of the College of Nursing at UIC, //and ... which is using warm booties as a way to ... The idea, says Shaver, is that better sleep occurs ...
... loss followed by weight gain is only a health risk ... are now well established to many. But weight, once lost,// ... that fluctuating weight may, in itself, predispose to heart disease ... a group of 5,428 middle-aged British men during a 12 ...
... observed that yoga therapy can reduce risk factors and improve ... aid improve physical, psychological and spiritual //health - or so ... England, reviewed the best evidence they could find on the ... - out of 11 - trials that were good enough ...
Cached Medicine News:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 2011 , ReportsnReports adds market ... & Forecasts to 2017 for Greece, Hungary & ... provide value (USD million), volume (units) and average ... within 10 market categories - Cardiac Assist Devices, ...
... Mass., Sept. 20, 2011 Intrinsic Therapeutics, a ... address the spine market,s many unmet needs, today ... and Chief Executive Officer. Mr. Hagan brings over ... field with significant expertise in product development, commercialization ...
Cached Medicine Technology:ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 2ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 3ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 4Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO 2
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Liquichek Urine Chemistry Control is a liquid product ideal for monitoring urine chemistry testing procedures. It provides assayed values for urine tests commonly performed on chemistry analyzers and...
Medicine Products: